TL;DR
This study reveals that a key DNA methyltransferase, DNMT3a, is reduced in the hippocampus of aged mice after anesthesia and surgery, leading to decreased DNA methylation and cognitive impairment. Restoring DNMT3a levels or reducing its downstream target, LRG1, can rescue these deficits, suggesting DNMT3a as a potential therapeutic target for preventing post-operative cognitive decline.
What Problem Does This Paper Address?
Perioperative neurocognitive disorder (PND) is a common and serious complication following surgery, particularly in older adults, leading to prolonged hospital stays and increased morbidity. While aging is a known risk factor, the precise molecular mechanisms linking anesthesia/surgery to cognitive decline in the aging brain remain largely unclear. Epigenetic changes, such as DNA methylation, are known to be altered during aging and are implicated in cognitive function. However, how anesthesia and surgery specifically impact these epigenetic mechanisms in the aging brain and contribute to PND has not been well understood. This paper aims to bridge this gap by investigating the role of DNA methylation, specifically focusing on DNA methyltransferases, in the development of PND in aged mice.
Methods
The researchers employed a multi-faceted approach to investigate the role of DNMT3a in PND:
- Animal Model: Aged mice underwent laparotomy under isoflurane anesthesia to mimic a PND model. Control groups received anesthesia without surgery or were handled normally.
- Molecular Analysis:
- RNA-Seq: To identify differentially expressed genes (DEGs) in the hippocampus after surgery.
- Reduced Representation Bisulfite Sequencing (RRBS): To generate a genome-wide map of DNA methylation changes in the hippocampus.
- qPCR and Western Blot: To quantify mRNA and protein levels of specific genes, including DNMT3a, LRG1, and TGF-β signaling components.
- Immunohistochemistry: To visualize the expression and localization of DNMT3a and LRG1 in different cell types within the hippocampus.
- 5-mC and 5-hmC Assays: To measure global DNA methylation and hydroxymethylation levels.
- Chromatin Immunoprecipitation (ChIP): To assess the binding of DNMT3a to the LRG1 promoter.
- Targeted Bisulfite Sequencing (TBS): To specifically examine DNA methylation at the LRG1 promoter region.
- Genetic Manipulation:
- AAV-mediated knockdown: Using shRNA to reduce DNMT3a expression in the hippocampus.
- AAV-mediated overexpression: Using AAV vectors to increase DNMT3a expression in the hippocampus.
- AAV-mediated knockdown of LRG1: To investigate the role of LRG1 in PND.
- Behavioral Tests:
- Open-Field Test (OFT): To assess general locomotor activity and anxiety-like behavior.
- Barnes Maze Test (BM): To evaluate spatial learning and memory.
- Fear Conditioning (FC): To assess associative learning and memory.
- Electrophysiology (fEPSP): To measure long-term potentiation (LTP) in hippocampal slices, a cellular correlate of learning and memory.
- Golgi Staining: To analyze dendritic spine density and complexity.
Datasets
Not explicitly detailed as separate datasets for training or evaluation in the traditional machine learning sense. The study generated its own data through experiments. RNA-Seq data was analyzed, and a portion of this data was deposited in the GEO database (GSE167953).
Key Insights and Ideas
- DNMT3a as a Key Player: The study strongly implicates DNMT3a, a DNA methyltransferase, as a critical mediator of anesthesia/surgery-induced cognitive impairment in aged mice. Its reduction appears to be a central event.
- Epigenetic Link to Cognitive Decline: The research provides a direct link between anesthesia/surgery, epigenetic modifications (specifically DNA methylation), and synaptic dysfunction leading to cognitive deficits.
- LRG1 as a Downstream Target: The identification of Leucine-Rich Repeat Containing Glycoprotein 1 (LRG1) as a key downstream target of DNMT3a is a significant finding. DNMT3a deficiency leads to hypomethylation of the LRG1 promoter, increasing LRG1 expression.
- TGF-β Signaling Activation: The increased LRG1 expression, in turn, activates the TGF-β signaling pathway, which ultimately impacts synaptic function and contributes to cognitive impairment. This reveals a novel mechanistic pathway.
- Therapeutic Potential: The study demonstrates that manipulating DNMT3a levels (overexpression) or its downstream effector (LRG1 knockdown) can effectively rescue synaptic deficits and cognitive impairments, highlighting promising therapeutic avenues for PND.
Key Results
- Anesthesia/surgery significantly reduced DNMT3a mRNA and protein levels in the hippocampus of aged mice.
- This reduction in DNMT3a led to a global decrease in 5-mC (DNA methylation) levels in the hippocampus.
- DNMT3a knockdown in aged mice resulted in impaired synaptic plasticity (reduced fEPSP slope and amplitude, decreased dendritic spine density) and significant cognitive deficits in Barnes Maze and Fear Conditioning tests.
- Genome-wide RRBS analysis revealed widespread DNA methylation changes, with a significant decrease in methylation at the LRG1 promoter region following surgery.
- Surgery increased LRG1 expression (mRNA and protein) in the hippocampus, which was correlated with decreased DNMT3a levels.
- Overexpression of DNMT3a in aged mice rescued the surgery-induced decrease in DNA methylation, reduced LRG1 expression, attenuated TGF-β signaling activation, and improved synaptic function and cognitive performance.
- Knockdown of LRG1 in aged mice also rescued surgery-induced cognitive deficits and synaptic impairments.
Limitations and Future Work
- Sole Downstream Target: The authors acknowledge that LRG1 may not be the sole downstream target of DNMT3a in PND. Other differentially methylated genes could also contribute to neuronal morphology remodeling and learning/memory deficits.
- Mechanisms of TGF-β Pathway: While the study shows that LRG1 activates TGF-β signaling, further exploration into the specific downstream molecules within the TGF-β pathway that mediate PND is warranted.
- Generalizability: The study was conducted in aged mice. Further research is needed to confirm these findings in other models and potentially in human studies.
- Anesthetic Specificity: While isoflurane was used, the effects of other anesthetics on DNMT3a and PND could be investigated.
The authors suggest that DNMT3a represents a promising therapeutic target for PND, and future work could focus on developing strategies to modulate DNMT3a activity or its downstream pathways to prevent or treat postoperative cognitive dysfunction.
Summary updated